You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Iovance reported third-quarter revenue of about $122 million, up 80% year-over-year, and 60% margin. It reaffirmed full-year revenue guidance of $410 to $420 million, expects cash to fund operations well into 2029, and plans a lung-cancer SBLA in 2027.
Iovance Biotherapeutics raised Full Year 2026 revenue guidance to $410M — $420M from $350M — $370M, reporting 3Q26 revenue of ~$122M and cash of ~$382M. It plans a 2027 Amtagvi supplemental Biologics License Application submission in second-line non-squamous mNSCLC.
Iovance reported product revenue increases of $54.0 million, or 80%, and $115.5 million, or 65%, for the three and nine months ended September 30, 2026. Net loss declined $69.0 million, or 76%, and $170.4 million, or 53%.
Iovance Biotherapeutics posted record third-quarter 2026 revenue of ~$122 million, up ~80%, with ~60% gross margin. It remained on track for 2026 revenue guidance of $410 to $420 million and reported ~$382 million cash expected to fund operations well into 2029.
Iovance Biotherapeutics, Inc. reported 24.6% ORR in 69 previously treated non-squamous mNSCLC patients, while a biomarker-enriched lifileucel subgroup achieved 59.1% ORR. POSITILITY enrollment begins November 2026, supporting a planned 2027 sBLA.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Record revenue of about $122 million, approximately 60% gross margin, strong Amtagvi growth, reaffirmed $410 to $420 million revenue guidance, a cash runway extending well into 2029, and a 59.1% response rate in a biomarker-selected lung cancer subgroup supported the outlook. Iovance nevertheless reported operating and net losses, while risks remain around clinical trials, manufacturing capacity, revenue generation and near-term profitability, market acceptance and reimbursement, and regulatory approval.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Amtagvi manufacturing turnaround time | 31 | Q2 2026 | — |
| Authorized treatment center (ATC) network | 95 | Q2 2026 | — |
| Cash position | $304M | As of June 30, 2026 | — |
| Gross margin | 56% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IOVA
this stock
Iovance Biotherapeutics, Inc.
|
$3.59B | +184.2% | +60.6% | — | 14.1% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.56B | +18.8% | +46.2% | 34.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.84B | +23.8% | +20.8% | 21.1 | 2.1% |
|
MRNA
Moderna, Inc.
|
$90.38B | +657.4% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.05B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Iovance Biotherapeutics raised Full Year 2026 revenue guidance to $410M — $420M from $350M — $370M, reporting 3Q26 revenue of ~$122M and cash of ~$382M. It plans a 2027 Amtagvi supplemental Biologics License Application submission in second-line non-squamous mNSCLC.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IOVA | -3.5% | -43.0% | +89.3% | -8.5% | +184.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -6.1% | -41.9% | +88.8% | -8.3% | +173.6% |
